MRSN vs. NLTX, NVCT, PBYI, IPHA, SPRO, VYGR, ALTS, EPRX, GALT, and DMAC
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Neoleukin Therapeutics (NLTX), Nuvectis Pharma (NVCT), Puma Biotechnology (PBYI), Innate Pharma (IPHA), Spero Therapeutics (SPRO), Voyager Therapeutics (VYGR), ALT5 Sigma (ALTS), Eupraxia Pharmaceuticals (EPRX), Galectin Therapeutics (GALT), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs. Its Competitors
Neoleukin Therapeutics (NASDAQ:NLTX) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Neoleukin Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -217.63%. Neoleukin Therapeutics' return on equity of -37.22% beat Mersana Therapeutics' return on equity.
Mersana Therapeutics has a consensus price target of $5.20, indicating a potential upside of 1,693.10%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Neoleukin Therapeutics.
In the previous week, Mersana Therapeutics had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Mersana Therapeutics and 1 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.67 beat Mersana Therapeutics' score of 0.00 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.
Neoleukin Therapeutics has higher earnings, but lower revenue than Mersana Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 13.0% of Mersana Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.
Summary
Mersana Therapeutics beats Neoleukin Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 7/4/2025 by MarketBeat.com Staff
